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Aim To investigate the association of gastric histological and 
endoscopic findings in patients with Helicobacter pylori (H. py-
lori), according to presence of seropositivity to 12 bacterial viru-
lence antigens.
Methods This is a cross-sectional single-center study of 360 
consecutive outpatients referred in the period of one year to 
upper gastrointestinal endoscopy because of dyspeptic com-
plaints. Patients sera were tested by Western blot method to 
determine the presence of serum antibodies to bacterial viru-
lence antigens – p120 (CagA – cytotoxin-associated antigen), 
p95 (VacA – vacuolating cytotoxin), p67 (FSH – flagellar sheath 
protein), p66 (UreB – urease enzyme heavy subunit), p57 (HSP 
homologue – heath shock protein homologue), p54 (flagellin), 
p33, p30 (OMP – outer membrane protein), p29 (UreA – urease 
enzyme light subunit), p26, p19, and p17. Upper gastrointesti-
nal endoscopy was performed, endoscopic diagnosis recorded, 
and 4 mucosal biopsy samples were obtained and assessed ac-
cording to Updated Sydney protocol.
Results The sera of 207 patients were analyzed. Thirty patients 
had gastric adenocarcinoma, 126 peptic ulcers, and 51 nor-
mal finding. p120 (CagA) seropositivity was significantly more 
often present in patients with higher activity grade in the an-
trum (P = 0.025), p30 in patients with greater inflammation in 
the antrum (P = 0.025) and the corpus (P = 0.010), p33 in pa-
tients with greater inflammation in the corpus (P = 0.050), and 
p19 (OMP) in patients with lower intestinal metaplasia grades 
in the corpus (P = 0.025). Seroreactivity to all other bacterial pro-
teins showed no association with the histological status of the 
stomach mucosa. Except for the seropositivity to protein p95 
(VacA), which was more often present in patients with duode-
nal ulcer (P = 0.006), there was no difference in seroreactivity to 
other bacterial proteins and upper gastrointestinal endoscopic 
findings.
Conclusions p120 (CagA), p33, p 30 (OMP), and p19 (OMP) 
seropositivity was more often present in patients with higher 
grades of the histological parameters of gastritis and seroposi-
tivity to protein p95 (VacA) with endoscopic presence of duo-
denal ulcer. Histological parameters of gastritis are more associ-
ated with bacterial virulence than endoscopic findings.
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Helicobacter pylori (H. pylori) is recognized as a major gastric 
pathogen with worldwide distribution (1). Estimated prev-
alence of H. pylori infection in Croatia is 60.4% (2). The per-
sistent colonization induces gastritis and in some patients 
peptic ulcer disease, atrophic gastritis, or gastric carcinoma 
(3). However, most of patients infected with H. pylori nev-
er develop cancer or ulcer disease and there is a need to 
identify additional factors that may influence the risk for 
development of such diseases. The outcome of H. pylori 
infection is associated with specific (virulence associated) 
bacterial genotypes, environmental factors, and host’s im-
mune status (4). A number of putative virulence factors for 
H. pylori infection have been identified, including CagA (cy-
totoxin-associated antigen), VacA (vacuolating cytotoxin), 
IceA (induced by epithelium antigen), BabA (blood-group 
antigen-binding adhesin), etc. It is likely that every other 
factor that results in increased inflammation will also con-
sequently increase the risk of a disease occurrence.
Presently, the only reliable way to identify the disease as-
sociated with H. pylori infection remains endoscopic ex-
amination combined with histological assessment of the 
gastric mucosa (5). The bacterial virulence antigens elicit 
specific antibodies during infection. However, the value 
of these antibodies as predictive factors for the severity of 
the disease remains controversial (6-15). So far, several in-
vestigations on the subject have been done, such as de-
tecting the level, specificity, or presence of isotypes of se-
rum H. pylori antibodies (16-22). Because disease outcome 
depends on both the strain characteristics and the host’s 
response, the serum antibody response to virulence anti-
gens could provide clues in predicting the presence and 
severity of associated diseases (23,24). On the other hand, 
since subjects without manifest disease also have strains 
bearing this or other virulence antigens, it seems that the 
disease could not be attributed to one virulence antigen 
alone. Thus, other virulence antigens may also be impor-
tant. The exact role of other bacterial virulence antigens – 
p67 (FSH – flagellar sheath protein), p66 (UreB – urease en-
zyme heavy subunit), p57 (HSP homologue – heath shock 
protein homologue), p54 (flagellin), p33, p30 (OMP – outer 
membrane protein), p29 (UreA – urease enzyme light sub-
unit), p26, p19 (OMP), and p17 in the pathogenesis of gas-
trointestinal diseases is still unclear.
In this study, we aimed to investigate the association of 
gastric histological and endoscopic findings in H. pylori-
positive patients according to presence of seropositivity to 
12 bacterial virulence antigens. Since both bacterial viru-
lence antigens and pattern of H. pylori gastritis may con-
tribute to development of clinically relevant gastroduode-
nal disease, we wanted to determine the antibodies which 
are most associated with higher grades of histology find-
ings of gastritis, atrophy, or intestinal metaplasia and differ-
ent clinical diseases (peptic ulcer, gastric cancer, and non-
ulcer dyspepsia).
MeThodS
Patients
In 2000, 360 consecutive outpatients referred to upper gas-
trointestinal endoscopy because of dyspeptic complaints 
were screened for H. pylori infection. Before entering the 
study, all patients provided written informed consent. The 
research protocol was approved by the Clinical Research 
Ethical Committee of the University Hospital Merkur in Za-
greb. All procedures were in accordance with the Declara-
tion of Helsinki, revision 2008 (25).
Two hundred and seven patients were eligible for the 
study. Inclusion criteria for the study were age over 18, be-
ing positive to H. pylori (proven by histology and serology), 
and no data about previous eradication treatment for H. 
pylori infection. The exclusion criteria were previous erad-
ication treatment; any antimicrobial treatment 2 months 
preceding the study; concomitant medication with bis-
muth preparations, proton pump inhibitors, H2-receptor 
antagonists, or non-steroid anti-inflammatory drugs; oth-
er serious illnesses; and history of gastric surgery. H. py-
lori positive status was proven by histology and serology 
(Western blot).
At examination, upper gastrointestinal endoscopy was 
performed and 4 gastric mucosa biopsy samples were ob-
tained (2 from the antrum and 2 from the corpus). Addi-
tionally, 1 vial of venous blood was obtained for serological 
examination. According to endoscopic findings, patients 
were divided into 5 groups as follows: normal mucosa (N), 
duodenal ulcer (D), gastric ulcer (V), duodenal and gastric 
ulcer (VD), and gastric adenocarcinoma (C).
histology
For histological examination, 4 biopsy samples were ob-
tained: 2 from the antrum and 2 from the corpus of gastric 
mucosa. The biopsy samples were embedded in paraffin 
wax and stained with hematoxylin and eosin, modified 
2% Giemsa stain, and periodic acid Schiff (PAS). All sam-
ples were analyzed for H. pylori density, activity (in-
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tensity of polymorphonuclear cells infiltrates), inflammation 
(intensity of mononuclear cells infiltrates), atrophy, and in-
testinal metaplasia, as stipulated by Updated Sydney system 
classification (26). All parameters were graded as 0 – none, 
1 – mild, 2 – moderate, or 3 – marked. Intestinal metaplasia 
was recognized morphologically with the presence of gob-
let cells, absorptive cells, and cells resembling colonocytes. 
The results from two antrum or corpus biopsy samples were 
combined and whenever differences were observed, the 
highest score was considered for statistical analysis.
Serology
Sera analysis was performed with commercially available 
Anti-H. pylori -Western blot test kit (Western blot, Euro-
immun Medizinische Labordiagnostika AG, Lubeck, Ger-
many). The procedure was performed according to man-
ufacturer’s instructions. Test is based on detection of anti 
H. pylori antigens IgG antibodies to 12 H. pylori specific 
and unspecific (cross-reacting or undefined) antigens. 
Antigen source for this commercially available anti-H. 
pylori-Western blot test is provided by the H. pylori type 
strain (27).
Serum samples were assayed for 12 antibodies to H. py-
lori antigens: p120 (CagA), p95 (VacA), p67 (FSH), p66 
(UreB), p57 (HSP homologue), p54 (flagellin), p33, p30 
(OMP), p29 (UreA), p26, p19 (OMP), and p17 by Western 
blot method. Proteins p 120 (CagA), p 95 (VacA), p33, p30 
(OMP), p29 (UreA), p26, p19 (OMP), p17 are H. pylori strain 
specific antigens and p67 (FSH), p66 (UreB), p57 (HSP ho-
mologue), p54 (flagellin) are cross-reacting or undefined 
antigens.
Statistical analysis
The associations between H. pylori individual virulence an-
tigens and presence of mucosal histological changes or 
clinical disease were analyzed using χ2 test. Odds ratios 
(OR) with confidence intervals were assessed by bivariate 
logistic regression. The t test was used to analyze the age 
distribution between the different patients groups. STATIS-
TICA for Windows, release 5.5 H (StatSoft, Tulsa, OK, USA) 
and SPSS for Windows, release 17.01 (SPSS Inc., Chicago, IL, 
USA) were used in statistical analysis.
ReSulTS
Study population
All 207 patients included in the study were H. pylori posi-
tive, confirmed by histology and serology. Among them, 
113 were men, with mean age ± standard deviation of 
58.0 ± 14.1 years and 94 were women, 57.9 ± 14.7 years old 
(P = 0.960). In Table 1, demographic data, endoscopic diag-
nosis, and serological and pathohistological findings of all 
207 patients are presented.
Inflammation of the corpus mucosa was present in 91.1% 
patients, activity (intensity of polymorphonuclear cells in-
TABle 1. demographic, endoscopic, serological, and patohistological findings of all 207 Croatian patients with benign and malignant 
gastroduodenal diseases
 
demographic or
 
No. (%)
 
Virulence
Finding 
No. patients, %)
 
Pathohistological
Finding
(No. patients, %)
endoscopic parameter patients antigens positive negative finding * positive negative
Age (mean ± standard deviation) 54.89 ± 14.3 P 120 (CagA) 189 (91.3)  18 (8.7) Corpus:
Men 113 (54.6) P 95 (VacA) 157 (75.8)  50 (24.2) inflammation 201 (97.1)   6 (2.9)
women  94 (45.4) P 67 (flagellin)  83 (40.1) 124 (59.9) activity 104 (50.2) 103 (49.8)
Endoscopic finding: P 66 (ureB) 130 (62.8)  77 (37.2) atrophy  15 (7.2) 192 (92.8)
gastric ulcer (V)  46 (22.2) P 57 (heath shock 149 (71.9)  58 (28.1) intestinal metaplasia 23 (11.1) 184 (88.9)
duodenal ulcer (D)  68 (32.8) protein homologue) Antrum:
gastric carcinoma (C)  30 (14.5) P 54 (flagellin)  50 (24.1) 157 (75.9) inflammation 203 (98.1)   4 (1.9)
normal mucosa (N)  51 (24.6) P 33  52 (25.1) 155 (74.9) activity 153 (73.9)  54 (26.1)
gastric and duodenal ulcer (VD)  12 (5.8) P 30 (outer membrane 
protein)
 57 (27.5) 150 (72.5) atrophy  22 (10.6) 185 (89.4)
P 29 (ureA)  93 (44.9) 114 (55.1) intestinal metaplasia 48 (23.2) 159 (76.8)
P 26  87 (42.1) 120 (57.9)
P 19 (outer membrane 
protein)
111 (53.6)  96 (46.4)
P 17  76 (36.7) 131 (63.3)
*According to updated Sydney system classification (26).
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filtrates) was found in 50.1%, atrophy in 7.2%, and intestinal 
metaplasia in 11.1%. Figure 1 represents distribution of dif-
ferent grades of pathohistological parameters of gastritis in 
the corpus of patients with benign and malignant gastro-
duodenal diseases.
Pathohistological analysis of the antrum mucosa revealed 
inflammation in 51.2% patients, activity (intensity of poly-
morphonuclear cells infiltrates) was found in 74.9%, atro-
phy in 10.6%, and intestinal metaplasia in 23.2%. Figure 
2 shows the distribution of different grades of pathohis-
tological parameters of gastritis in the antrum mucosa of 
patients with benign and malignant gastroduodenal dis-
eases. Out of 30 patients with gastric adenocarcinoma, 23 
had intestinal and 7 diffuse cancer form. Of all patients, 18 
had tumor in the antrum and 12 in the corpus part of the 
stomach.
Correlation of h. pylori virulence antigens and gastric 
histology
The correlation of histological features and seropositivity 
status was significant for proteins p120 (CagA), p30 (OMP), 
p33, and p19 as follows: p120 (CagA) seropositivity was 
associated with higher activity grades (P = 0.025) in the 
antrum, p30 (OMP) seropositivity with higher inflamma-
tion grades in both the corpus (P = 0.010) and the antrum 
(P = 0.025), and antigen p33 with higher inflammation 
grades in the corpus (P = 0.050). Contrary to this, seropos-
itivity to p19 (OMP) antigen was associated with lower 
grades of intestinal metaplasia in the corpus (P = 0.025) of 
gastric mucosa (Table 2). There was no significant differ-
ence in the distribution of histological parameters of gas-
tritis with respect to the serological status of other bacte-
rial virulence antigens.
Correlation of h. pylori virulence antigens and endo-
scopic diagnosis
Seropositivity to antigen p95 (VacA) was significantly more of-
ten observed in patients with duodenal ulcer and less often in 
those with normal mucosa and gastric carcinoma (P = 0.006). 
Sensitivity and specificity of positive serology finding to p95 
(VacA) to detect patients with duodenal ulcer were 91.2% 
and 31.7%, respectively. Also, sensitivity and specificity of 
positive serology finding to detect patients with gas-
Figure 1.
distribution of different grades (light grey – no change, medium grey 
– mild, dark grey – moderate, white – marked) of histological parameters 
(inflammation, activity, atrophy, and intestinal metaplasia) of gastritis in 
corpus mucosa of 207 Croatian patients with benign and malignant gas-
troduodenal diseases.
Figure 2.
distribution of different grades (light grey – no change, medium grey 
– mild, dark grey – moderate, white – marked) of histological parameters 
(inflammation, activity, atrophy, and intestinal metaplasia) of gastritis in 
the antrum mucosa of 207 Croatian patients with benign and malignant 
gastroduodenal diseases.
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tric carcinoma were 60.0% and 21.5%, to detect patients with 
gastric ulcer were 71.7% and 23.0%, to detect patients with 
simultaneous gastric and duodenal ulcer were 66.7% and 
23.6%, and to detect patients with normal mucosa finding 
were 70.6% and 22.4%, respectively. There was no association 
between seropositivity to any other of 11 H. pylori virulence 
proteins and endoscopic finding. The distributions of differ-
ent endoscopy findings and antibodies to H. pylori viru-
lence antigens are summarized in Table 3.
diSCuSSioN
The results of our study demonstrated the association of 
seropositivity to p120 (CagA), p33, and p30 (OMP) with 
higher grades of the histological parameters of gastritis, 
and seropositivity to p19 (OMP) with lower grades of in-
testinal metaplasia. Only seropositivity to p95 (VacA) was 
strongly associated with endoscopic presence of duode-
nal ulcer.
TABle 2. Presence of different grades of histological parameters of gastritis in patients serologicaly positive and negative to H. pylori 
virulence proteins p120 (CagA), p19, p30 (oMP), and p33 (n = 207)
Antibodies χ2 test Bivariate logistic regression
histology* grade negative positive sensitivity specificity P P odds ratio (95% Ci)
p 19
Intestinal metaplasia, corpus 0  79 105
0.025 0.005 0.441 (0.248-0.785)
1   4   3  2.70  95.83
2  11   3  2.70  88.54
3   2   0  0.00  97.92
all  96 111
p 30 (outer membrane protein)
Inflammation, corpus 0   6   0
0.010 0.003 1.956 (1.252-3.055)
1  88  27 47.37  41.33
2  49  20 35.09  67.55
3   7  10 17.54  95.33
all 150  57
p 30 (outer membrane protein)
Inflammation, antrum 0   1   3
0.025 0.367 1.224 (0.789-1.900)
1  54  16 28.07  64.00
2  80  26 45.61  46.67
3  15  12 21.05  90.00
all 150  57
p 33
Inflammation, corpus 0   4   2
0.050 0.026 1.666 (1.061-2.616)
1  95  20 38.46  38.71
2  45  24 46.15  70.97
3  11   6 11.54  92.90
all 155  52
p 120 (CagA)
Activity, antrum 0   4  50
0.025 0.095 2.295 (0.911-3.175)
1  14  77 40.74  22.22
2   0  47 24.87 100.00
3   0  15  7.94 100.00
all  18 189
*According to updated Sydney system classification (26).
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So far, many attempts have been made to find serological 
markers of H. pylori virulence, which could be correlated 
with the severity of the H. pylori-associated diseases. These 
studies indicate that seropositivity to some H. pylori anti-
gens could be used as serological marker for bacterial viru-
lence (17-20,28,29).
When we compared serology findings to 12 H. pylori viru-
lence antigens with gastric mucosa histopathological find-
ings, we noticed that p120 (CagA) seropositivity was asso-
ciated with higher activity grades in the antrum, p30 (OMP) 
seropositivity with higher inflammation grades in both the 
antrum and corpus, p33 seropositivity with higher inflam-
mation grades in the corpus, and p19 (OMP) seropositivity 
with lower grades of intestinal metaplasia in the corpus. 
Protein CagA is the most investigated H. pylori virulence 
factor, but its connection with the presence of various mu-
cosal histological changes is still controversial and there 
are many studies with contradictory results (30-33). Our re-
sults are consistent with previous observations, in which 
CagA elicited high neutrophil accumulation, measured as 
inflammation activity in gastric mucosa (29). According to 
some studies, this can be related to strong stimulation of 
IL-8 production by CagA positive strains (34,35). There are 
no data on the association of seropositivity to proteins p30 
(OMP), p33, and p19 (OMP) and different patterns of gas-
tritis. The first step in all H. pylori-related diseases is emer-
gence of gastritis. Possible pathogenetic mechanisms in-
volved in the association of these proteins with higher 
grades of gastritis should be additionally investigated re-
garding implications in the occurrence of gastroduodenal 
diseases.
Proteins p95 (VacA), p67 (FSH), p66 (UreB), p57 (HSP ho-
mologue), p54 (flagellin), p29 (UreA), p26, and p17 sero-
positivity were not associated with the histological pat-
terns of gastritis. Several studies consistently showed that 
different vacA genotypes were associated with disease 
appearance in patients from various countries. On the 
other hand, there are different VacA isoforms with 
TABle 3. Serological findings for 12 H. pylori virulence antigens in various benign and malignant gastroduodenal diseases (n = 207)
endoscopic finding* χ2 test Bivariate logistic regression
Antigen d C N V Vd P odds ratio (95% confidence interval) P
p120 positive 65 28 43 42 11
0.301 0.794 (0.511-1.233) 0.304
negative  3  2  8  4  1
p95 positive 62 18 36 33  8
0.006 1.147 (0.862-1.524) 0.347
negative  6 12 15 13  4 
p67 positive 24 11 27 15  6
0.209 1.264 (0.981-1.628) 0.070
negative 44 19 24 31  6
p66 positive 42 23 32 27  6
0.455 0.854 (0.663-1.101) 0.233
negative 24  7 19 19  6
p57 positive 48 22 40 30  9
0.691 1.128 (0.860-1.479) 0.384
negative 20  8 11 16  3
p54 positive 14 10 13 11  2
0.680 0.872 (0.656-1.159) 0.347
negative 54 20 37 35 10
p33 positive 14  5 19 12  2
0.174 1.199 (0.902-1.593) 0.211
negative 54 25 32 34 10
p30 positive 20 10 17  7  3
0.291 1.092 (0.831-1.434) 0.529
negative 48 20 34 39  8
p29 positive 28 16 24 19  6
0.790 0.983 (0.770-1.256) 0.894
negative 40 14 27 27  6
p26 positive 28 13 28 12  6
0.391 1.272 (0.989-1.635) 0.061
negative 40 17 23 34  6
p19 positive 41 11 31 20  8
0.076 1.409 (1.094-1.814) 0.008
negative 27 19 20 26  4
p17 positive 28 12 19 13  4
0.699 1.023 (0.795-1.316) 0.859
negative 40 18 32 33  8
all 68 30 51 46 12
*Abbreviations: C – carcinoma, d – duodenal ulcer, N – normal mucosa, V – gastric ulcer, Vd – gastric and duodenal ulcer.
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distinct antigenic properties and, consequently, multiple 
forms of VacA could elicit different antibody responses in 
H. pylori-positive humans (36). Based on our findings, we 
can conclude that present serology testing to antigen 
VacA was not sensitive enough to predict toxic and his-
tolopathological effects of vacuolization toxin. Obviously. 
distinct serological response to VacA toxin cannot differen-
tiate between more and less toxic isoforms of VacA related 
with different grades of histopathological findings. Bet-
ter results in this field of research could be provided with 
investigation of different vacA genotypes in relation with 
presence of various histopathological findings.
Also, none of the tested serologic markers have been as-
sociated with appearance of atrophic gastritis. It may be 
necessary to look for other antigens, or the atrophy could 
be unrelated to serologic status to H. pylori virulence anti-
gens.
In the present study, we found that only antibodies to the 
protein p95 (VacA) were more frequently than other endo-
scopic findings present in patients suffering from duode-
nal ulcers. Thus, the anti-VacA antibody is a more power-
ful marker of ulcers than anti-CagA. This is not surprising, 
because the vacuolizating toxin has been suspected to 
be involved in the development of mucosal ulcerous le-
sions (37-39). It has been reported that the toxin causes 
epithelial damage, but appears to have little effect on in-
flammatory cell infiltration. These results are in agreement 
with previous studies, which showed that anti-CagA, anti-
VacA, and anti-p35 appear to be the best markers of ul-
cers (40). However, the clinical relevance of this association 
remains controversial (15). Contrary to this, we found no 
association of anti-CagA antibodies to endoscopic find-
ing. Explanation of the discrepancy could be that in some 
areas there is high prevalence of CagA- and VacA-positive 
individuals. In our study, 91.3% of patients were CagA and 
75.8% VacA positive. Another explanation could be the 
fact that peptic ulcers may be intermittently present and 
certain patients may be non-ulcerous at the time of en-
doscopic examination but may later evolve to an ulcerous 
state. Other authors have attempted to establish correla-
tions between certain antibody patterns and gastric can-
cer (20). We also found anti-p95 (VacA) to be less frequent-
ly detected in patients with endoscopic finding of gastric 
carcinoma or normal mucosa than peptic ulcer. Possible 
clinical implications of the observed phenomena could 
be used in future in order to distinguish patients infected 
with more virulent strains of bacteria, especially those 
infected with therapy resistant strains. Also, proteins 
which elicit strong serological response in greater number 
of patients could be possibly used as a part of anti H. pylori 
vaccine. However, in order to confirm its real prognostic 
significance and clinical usefulness of these observations, 
a larger study population is needed.
A possible limitation of the study is that sample size cal-
culation or power analysis was not performed. Marginal 
results of statistical significance were observed in differ-
ence of distributions of various grades of corpus inflam-
mation and intestinal metaplasia according to anti-p120 
(CagA) finding (data not shown). Additional investigation 
with greater number of patients could answer the ques-
tion on true association of protein CagA and histopatho-
logical patterns of gastritis. Moreover, the presence of the 
bacterial virulence antigens was evaluated indirectly by 
host serological response only. Many of the tested bacte-
rial virulence antigens are highly immunogenic and can in-
duce antibody response in almost all patients (41). But, it is 
generally known that serological response depends on an-
tigen type and immunological reactivity of the host. Some 
patients are infected with more than one type of bacteria 
possessing a variety of different (more or less virulent) pro-
teins encoded by different genotypes of virulence genes. 
All of this explains why negative serological response does 
not always implicate H. pylori negativity to tested virulence 
antigen. Seropositivity to specific antigen does not abso-
lutely indicate the relationship with pathogenesis of spe-
cific disease. Furthermore, these observations indicate that 
there is a need for future research into the pathogenesis of 
gastroduodenal diseases.
In conclusion, histological parameters of gastritis show bet-
ter association with bacterial virulence than an endoscopic 
finding. However, no single entity or array of antigens has 
yet been identified that can serve as a serological marker(s) 
for predicting the development of specific gastric disease. 
This could be attributed to the role of other factors that 
govern disease expression, eg, other undetected virulence 
antigens, changes in gastric physiology, or host immune-
inflammatory response (42).
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